Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 known ✓ | P04062 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL5311459 | 1.00 | LMNA (0.46) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL8167949 | 1.00 | LMNA (0.46) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL188002 | 1.00 | LMNA (0.46) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL9581037 | 1.00 | LMNA (0.46) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL28683781 | 0.98 | LMNA (0.44) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL9296176 | 0.98 | CYP3A4 (0.50) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL15993811 | 0.94 | LMNA (0.41) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL14856284 | 0.94 | LMNA (0.41) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL30402903 | 0.94 | LMNA (0.52) | LMNACYP3A4MEN1KMT2ASLC5A7 | |
| Cadaverine Tartrate SCHEMBL188000 | 0.94 | LMNA (0.52) | LMNACYP3A4MEN1KMT2ASLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3599276-A1 | IMPROVED CELL CULTURE MEDIUM | Novartis AG (CH) | 2020-01-29 | — | — | EP | disclosed |
| EP-2563903-B1 | IMPROVED CELL CULTURE MEDIUM | NOVARTIS AG (CH) | 2019-08-21 | — | — | EP | disclosed |
| US-9243224-B2 | Cell culture medium | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150218509-A1 | CELL CULTURE MEDIUM | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-8986957-B2 | Cell culture medium | NOVARTIS AG (CH) | 2015-03-24 | — | — | US | disclosed |
| US-20130102032-A1 | CELL CULTURE MEDIUM | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| EP-2563903-A1 | IMPROVED CELL CULTURE MEDIUM | Novartis AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134921-A1 | IMPROVED CELL CULTURE MEDIUM | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |